On August 19, 2026, the U.S. Food and Drug Administration granted accelerated approval to Genglycos (pariglasgene brecaparvovec-opnr) for use in adults and pediatric patients 8 years of age and older with glycogen storage disease type Ia (GSDIa). The approved indication is to reduce daily cornstarch intake as an adjunct to nutritional management. This is the first FDA-approved therapy specifically for GSDIa. The approval was issued under the accelerated approval pathway, which permits approval based on a surrogate or intermediate clinical endpoint reasonably likely to predict clinical benefit, with a requirement for confirmatory post-approval trials.
GSDIa is an inherited genetic disorder caused by mutations that result in deficiency of the enzyme glucose-6-phosphatase (G6PC). G6PC normally allows the liver and kidneys to release free glucose from stored glycogen into the bloodstream, maintaining blood glucose during fasting and between meals. Without functional G6PC, individuals are at risk for severe hypoglycemia when fasting, and the condition can lead to long-term metabolic complications affecting organs and tissues.
Current management emphasizes careful medical monitoring and intensive dietary measures. Patients commonly require frequent meals, avoidance of simple sugars, and continuous dietary supplementation with uncooked or specially formulated cornstarch (a slow-digesting complex carbohydrate) to prevent hypoglycemia. These measures are typically lifelong and around-the-clock.
Genglycos is a one-time gene therapy using an adeno-associated virus serotype 8 (AAV8) vector to deliver a functional G6PC gene to the liver. The therapy is intended to restore the deficient enzyme activity required to release stored glucose and thereby support more stable blood glucose levels during fasting. The approved use is as an adjunct to, not a replacement for, appropriate dietary management.
The accelerated approval was supported by a randomized, double-blind, placebo-controlled study with 48 weeks of follow-up after dosing, along with data from a second clinical study. The primary endpoint in the randomized study was reduction in daily cornstarch intake, a surrogate endpoint chosen by the agency. Patients treated with Genglycos showed a statistically significant mean reduction from baseline in daily cornstarch intake of 31% compared with placebo.
A secondary endpoint showed a mean reduction from baseline of one cornstarch dose per day in the Genglycos group versus placebo. The company and FDA considered reduction in cornstarch intake a surrogate reasonably likely to predict clinical benefit, which supported accelerated approval. The Genglycos-treated group experienced a numerical mean 3% increase in the percentage of glucose values in the hypoglycemic range (< 70 mg/dL) compared with placebo.
Because this approval is accelerated, the manufacturer is required to complete additional clinical trials to confirm the therapy’s long-term effectiveness.
Across two clinical studies, serious adverse reactions reported in Genglycos-treated patients included anaphylaxis, adrenal insufficiency, elevated lactate levels, and hypoglycemia. The most commonly reported adverse reactions were increased transaminases (liver enzyme elevations), nausea, headache, constipation, and hyperglycemia.
Genglycos-treated patients had a higher rate of hypertriglyceridemia, a metabolic marker of GSDIa, compared with placebo-treated patients (29% vs 8%). The prescribing information includes warnings about risks of anaphylaxis, liver toxicity, adrenal insufficiency, and potential tumorigenicity. The product should not be used during pregnancy.
The application for Genglycos received several regulatory designations: the FDA granted regenerative medicine advanced therapy (RMAT) and Fast Track designations, and the marketing application received a Rare Pediatric Disease Priority Review Voucher. The approval was granted to Ultragenyx Pharmaceutical, Inc. As an accelerated approval, confirmatory clinical trials are required to verify and describe clinical benefit.
This approval provides the first approved therapeutic option specifically targeting the underlying genetic defect in GSDIa for patients aged 8 years and older. Clinicians should note that the approved effect is on a surrogate endpoint—reduction in daily cornstarch intake—and that additional data are required to confirm long-term benefit.
Prescribers must balance potential benefits against the reported safety signals, including anaphylaxis, liver enzyme elevations, adrenal insufficiency, hypertriglyceridemia, and possible tumorigenicity. Genglycos is a one-time AAV8-based gene therapy administered as a single dose and is intended to be used in conjunction with appropriate dietary management rather than as a standalone replacement for established nutritional care. It is contraindicated during pregnancy.
The FDA listed media and consumer contacts for more information. The accelerated approval and related regulatory designations are documented in the FDA press release. The FDA emphasized the need for confirmatory trials to demonstrate long-term clinical benefit and directed readers to prescribing information for complete safety warnings and precautions.
Content current as of 08/19/2026. The FDA granted accelerated approval to Genglycos to Ultragenyx Pharmaceutical, Inc.